Melatonin for sleep disturbance in breast cancer patients
Phase II randomised control trial of melatonin versus placebo for the management of sleep disturbance in women with early stage breast cancer on adjuvant endocrine therapy
University of Sydney
51 participants
Sep 1, 2022
Interventional
Conditions
Summary
The purpose of this study is to see if melatonin supplementation can help improve sleep in women receiving hormone blocking therapy for breast cancer. Who is it for? You may be eligible for this study if you are aged 18 or over, have stage 1-3 breast cancer, are taking hormone blocking therapy and have trouble sleeping. Study details Participants in this study will be randomised by chance into two groups. One group will take melatonin tablets every evening before bed for 12 weeks. The other group will take a placebo tablet every evening before bed for 12 weeks. Neither the participants nor the researchers will know which participants are taking which tablets. All participants will complete questionnaires, complete a medication diary and wear an atigraph watch to measure your sleep. It is hoped this research will demonstrate the usefulness of melatonin in improving sleep in breast cancer patients.
Eligibility
Inclusion Criteria13
- a) Age >=18 years
- b) Female
- c) Stage I-III breast cancer
- d) Stable on adjuvant endocrine therapy for >=3 months with:
- i. Aromatase inhibitor (letrozole, anastrozole or exemestane)
- ii. Tamoxifen
- iii. +/- ovarian suppression with gonadotropin releasing hormone agonist
- e) Completed primary adjuvant breast cancer treatment (surgery +/- chemotherapy +/- radiotherapy) >=6 months previously (patients can still be receiving adjuvant trastuzumab)
- f) ECOG 0-2
- g) Self-reported sleep disturbance that started or worsened after breast cancer diagnosis or commencing endocrine therapy
- h) Poor sleep quality defined as PSQI score >=5
- i) Willing and able to complete study questionnaires in English
- j) Written informed consent to participate in the trial
Exclusion Criteria13
- a) Metastatic breast cancer (stage IV)
- b) Currently on hormone replacement therapy (HRT) or oral contraceptive pill (OCP)
- c) Diagnosis of obstructive sleep apnoea or other sleep disorder
- d) Use of melatonin or other pharmaceutical interventions for sleep <=14 days of study enrolment e.g. benzodiazepines, zolpidem or zopiclone
- e) Working >1 overnight shift per fortnight on a regular basis
- f) Pregnant or breastfeeding
- g) Use of warfarin if INR <1 or >4 (sub- therapeutic or supra-therapeutic INR)
- h) Uncontrolled seizure disorder
- i) Started new anti-depressant medication or dose change of existing anti-depressant medication within last 3 months
- j) Currently on agomelatin (Valdoxan) (due to interaction with melatonin)
- k) Severe renal impairment with estimated glomerular filtration rate (eGFR) <30
- l) Decompensated liver cirrhosis or hepatic impairment with raised bilirubin >=3x ULN and/or raised alanine aminotransferase or aspartate aminotransferase >=5x ULN
- m) Known hypersensitivity or allergy to melatonin
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Oral melatonin slow release 2mg tablets taken daily 1-2 hours before bedtime for 12 weeks Participants will complete a medication diary and pill counts will be performed
Locations(4)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12619001284156